Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Searle

Showing results (241-250 of 268) with videos related to

Pageof 27
Sort By:
Journal of Medicinal Chemistry|October 31, 2003
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapyLongqin Hu, Chengzhi Yu, Yongying Jiang, et al.
Infection Control and Hospital Epidemiology|October 11, 2024
Enabling laboratory readiness and preparedness for the evaluation of suspected viral hemorrhagic fevers: development of a laboratory toolkitSarah E Turbett, Jacob E Lazarus, Mia A Nardini, et al.
British Journal of Cancer|March 1, 1986
The potential of carboxypeptidase G2-antibody conjugates as anti-tumour agents. I. Preparation of antihuman chorionic gonadotrophin-carboxypeptidase G2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitroF Searle, C Bier, R G Buckley, et al.
Infection Control and Hospital Epidemiology|November 27, 2025
Real learning in a virtual world: a pilot study of the impact of virtual reality training on IPC knowledge and confidenceMichelle S Jerry, Vianelly García, Andrea S Greenfield, et al.
The Biochemical Journal|June 18, 2021
The structures of E. coli NfsA bound to the antibiotic nitrofurantoin; to 1,4-benzoquinone and to FMNMartin A Day, David Jarrom, Andrew J Christofferson, et al.
International Journal of Molecular Sciences|March 29, 2023
Structure and Dynamics of Three <i>Escherichia coli</i> NfsB Nitro-Reductase Mutants Selected for Enhanced Activity with the Cancer Prodrug CB1954Martin A Day, Andrew J Christofferson, J L Ross Anderson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 10, 2001
Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumorsA H Djeha, T A Thomson, H Leung, et al.
Advances in Experimental Medicine and Biology|February 23, 1999
Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase geneP F Searle, S J Weedon, I A McNeish, et al.
Lancet (London, England)|October 2, 1982
Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibodyR H Begent, P A Keep, A J Green, et al.
Gene Therapy|December 15, 2007
Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivoC L White, T Menghistu, K R Twigger, et al.
Pageof 27

Showing results (241-250 of 268) with videos related to

Sort By:
Pageof 27
Journal of Medicinal Chemistry|October 31, 2003
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapyLongqin Hu, Chengzhi Yu, Yongying Jiang, et al.
Infection Control and Hospital Epidemiology|October 11, 2024
Enabling laboratory readiness and preparedness for the evaluation of suspected viral hemorrhagic fevers: development of a laboratory toolkitSarah E Turbett, Jacob E Lazarus, Mia A Nardini, et al.
British Journal of Cancer|March 1, 1986
The potential of carboxypeptidase G2-antibody conjugates as anti-tumour agents. I. Preparation of antihuman chorionic gonadotrophin-carboxypeptidase G2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitroF Searle, C Bier, R G Buckley, et al.
Infection Control and Hospital Epidemiology|November 27, 2025
Real learning in a virtual world: a pilot study of the impact of virtual reality training on IPC knowledge and confidenceMichelle S Jerry, Vianelly García, Andrea S Greenfield, et al.
The Biochemical Journal|June 18, 2021
The structures of E. coli NfsA bound to the antibiotic nitrofurantoin; to 1,4-benzoquinone and to FMNMartin A Day, David Jarrom, Andrew J Christofferson, et al.
International Journal of Molecular Sciences|March 29, 2023
Structure and Dynamics of Three <i>Escherichia coli</i> NfsB Nitro-Reductase Mutants Selected for Enhanced Activity with the Cancer Prodrug CB1954Martin A Day, Andrew J Christofferson, J L Ross Anderson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 10, 2001
Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumorsA H Djeha, T A Thomson, H Leung, et al.
Advances in Experimental Medicine and Biology|February 23, 1999
Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase geneP F Searle, S J Weedon, I A McNeish, et al.
Lancet (London, England)|October 2, 1982
Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibodyR H Begent, P A Keep, A J Green, et al.
Gene Therapy|December 15, 2007
Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivoC L White, T Menghistu, K R Twigger, et al.
Pageof 27